Abcuro is a company founded in 2018 headquartered in the United States. Its most recent tracked round is Series-c-plus. Brouky records 3 investors associated with the company.
Abcuro is a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T cells. Its lead candidate, ulviprubart (ABC008), is a first-in-class monoclonal antibody targeting killer cell lectin-like receptor G1 (KLRG1), designed to selectively deplete highly cytotoxic T cells implicated in tissue damage.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.